X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AUROBINDO PHARMA ALKEM LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x - 15.6 - View Chart
P/BV x 7.5 4.0 187.7% View Chart
Dividend Yield % 0.6 0.4 148.0%  

Financials

 ALKEM LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AUROBINDO PHARMA
Mar-17
ALKEM LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589895 177.5%   
Low Rs1,232622 198.1%   
Sales per share (Unadj.) Rs417.5254.6 164.0%  
Earnings per share (Unadj.) Rs56.339.3 143.3%  
Cash flow per share (Unadj.) Rs64.746.6 138.9%  
Dividends per share (Unadj.) Rs12.702.50 508.0%  
Dividend yield (eoy) %0.90.3 273.2%  
Book value per share (Unadj.) Rs292.9160.0 183.1%  
Shares outstanding (eoy) m119.57585.88 20.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.4%   
Avg P/E ratio x25.119.3 129.7%  
P/CF ratio (eoy) x21.816.3 133.9%  
Price / Book Value ratio x4.84.7 101.5%  
Dividend payout %22.66.4 354.4%   
Avg Mkt Cap Rs m168,653444,390 38.0%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m9,17117,678 51.9%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m49,915149,157 33.5%  
Other income Rs m1,6451,159 142.0%   
Total revenues Rs m51,561150,316 34.3%   
Gross profit Rs m8,48234,343 24.7%  
Depreciation Rs m1,0064,276 23.5%   
Interest Rs m671667 100.5%   
Profit before tax Rs m8,45130,558 27.7%   
Minority Interest Rs m-11450 -226.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6067,597 21.1%   
Profit after tax Rs m6,73123,012 29.3%  
Gross profit margin %17.023.0 73.8%  
Effective tax rate %19.024.9 76.4%   
Net profit margin %13.515.4 87.4%  
BALANCE SHEET DATA
Current assets Rs m27,06292,062 29.4%   
Current liabilities Rs m15,32466,223 23.1%   
Net working cap to sales %23.517.3 135.7%  
Current ratio x1.81.4 127.0%  
Inventory Days Days67106 62.8%  
Debtors Days Days4168 61.0%  
Net fixed assets Rs m12,61062,919 20.0%   
Share capital Rs m239586 40.8%   
"Free" reserves Rs m34,49093,133 37.0%   
Net worth Rs m35,02793,719 37.4%   
Long term debt Rs m1,2121,814 66.8%   
Total assets Rs m54,387162,494 33.5%  
Interest coverage x13.646.8 29.1%   
Debt to equity ratio x00 178.7%  
Sales to assets ratio x0.90.9 100.0%   
Return on assets %13.614.6 93.4%  
Return on equity %19.224.6 78.3%  
Return on capital %24.932.7 75.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56375,838 8.7%   
Fx outflow Rs m3,01230,224 10.0%   
Net fx Rs m3,55245,613 7.8%   
CASH FLOW
From Operations Rs m7,25932,786 22.1%  
From Investments Rs m1,864-17,870 -10.4%  
From Financial Activity Rs m-9,273-19,153 48.4%  
Net Cashflow Rs m-150-4,239 3.5%  

Share Holding

Indian Promoters % 66.9 54.1 123.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.0 416.4%  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.2 -  
Shareholders   68,381 69,601 98.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   STERLING BIOTECH  SANOFI INDIA  DR. DATSONS LABS  ORCHID PHARMA LTD  NOVARTIS  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - AJANTA PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS